Univeristy of Nebraska-Lincoln (UNL) scientist Ana Maria Vélez is pioneering a genetic treatment to contain western corn rootworm. The research seeks to contain agricultural pests by targeting ...
LONDON--(BUSINESS WIRE)--Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference ...
It was not until 2018 that the US FDA approved the first therapy developed using the technique. Since then, there’s been a steady, but slow, number of RNAi treatments coming into the market. The ROBO ...
MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed ...
The global market for RNAi technology is estimated to increase from $2.1 billion in 2023 to reach $4.8 billion by 2029, at a compound annual growth rate (CAGR) of 14.8% from 2024 through 2029. The ...
Open Biosystems, Inc. has announced that the Peter MacCullum Cancer Centre has joined its Open Access RNAi Program. Through this program, the Peter MacCullum Cancer Centre has purchased Open ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ...
Report covers Silexion Therapeutics (NASDAQ: SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results